Comparative Pharmacology
Head-to-head clinical analysis: THYQUIDITY versus THYROLAR 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYQUIDITY versus THYROLAR 1.
THYQUIDITY vs THYROLAR-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone replacement; levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, regulating gene transcription and increasing metabolic rate.
Thyrolar-1 is a combination of levothyroxine (T4) and liothyronine (T3). T4 is converted to the active hormone T3 in peripheral tissues. Both forms bind to thyroid hormone receptors, which regulate gene transcription, influencing metabolism, growth, and development.
50 mg orally once daily, with or without food.
Oral: 30-60 mg liothyronine (T3) daily, typically initiated at 15 mg/day and titrated upward based on clinical response. Usual maintenance dose 25-50 mg/day.
None Documented
None Documented
The terminal elimination half-life of levothyroxine is approximately 6-7 days in euthyroid individuals. In hyperthyroidism, half-life decreases to 3-4 days; in hypothyroidism, it can extend to 9-10 days. This long half-life supports once-daily dosing and allows for steady-state achievement in about 6-8 weeks.
Levothyroxine (T4): 6–7 days; Liothyronine (T3): 1–2 days. In hyperthyroidism, T4 half-life may be reduced to 3–4 days; in hypothyroidism, prolonged to 9–10 days.
Thyquidity (levothyroxine sodium) is primarily excreted via the kidneys as unchanged drug and metabolites. Approximately 20-40% of an oral dose is excreted in feces via biliary elimination, with the remainder eliminated renally. Up to 80% of an administered dose appears in urine as thyroxine and its metabolites, primarily glucuronide and sulfate conjugates.
Renal excretion of iodide; after deiodination of T3 and T4, iodine is excreted in urine (∼80%) and feces (∼20%).
Category C
Category C
Thyroid Hormone
Thyroid Hormone